June 14, 2019
Sumitomo Dainippon Pharma said on June 13 that it has revised its joint development and license pact with Japanese startup Healios on a therapy based on iPS cell-derived retinal pigment epithelial (RPE) cells, and will now be primarily responsible for...read more